Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Development of a therapy against metastatic bladder cancer using an interleukin-2 surface-modified MB49 bladder cancer stem cells vaccine

Fig. 1

Identification of MCSCs in CSCs characters. a FCM analysis showed that the fraction of CD44+CD133+ cells in the MCSCs population was larger than in MB49 cells. b WB analysis showed that CD133 and CD44 were abundantly expressed in MCSCs but poorly expressed in MB49 cells. β-actin was used as a protein loading control. c qPCR analysis revealed that the relative levels of CD133 and CD44 mRNA in MCSCs were higher in MB49 cells. d MCSCs exhibited higher cell viabilities after being exposed to different concentrations of paclitaxel and cisplatin. e In the transwell migration assay, the number of invasive MCSCs was higher than that of MB49 cells. f In xenograft formation experiments, MCSCs produced larger tumor volumes than MB49 cells did. *P < 0.05 (vs MB49 cells). MCSCs MB49 bladder cancer stem cells, CSCs cancer stem cells, FCM flow cytometry, WB Western blot, qPCR quantitative polymerase chain reaction

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512